Targeting the Hard-to-Treat In the evolving landscape of cancer research, precision medicine is becoming the gold standard. A recent clinical trial has shed light on invikafusp alfa (Invika), a novel T-cell therapy designed to address the complex challenges posed by treatment-resistant cancers. How Invikafusp Alfa Works Unlike traditional therapies that often affect healthy cells, this…